Royalty PharmaSTU:RPD +0.52%72 EBITDA Margin % is 89.31% as of Mar. 2026, which is 11% above its 10-year median of 80.15. GuruFocus rates STU:RPD with a GF Score™ of 72/100 and a GF Value™ of €32.95 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 944 Biotechnology companies, Royalty Pharma ranks better than 96.72% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Royalty Pharma's EBITDA for the
three
months ended in Mar. 2026 was €487 Mil. Royalty Pharma's Revenue for the
three
months ended in Mar. 2026 was €545 Mil. Therefore, Royalty Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was 89.31%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Royalty Pharma EBITDA Margin % Related Terms
Royalty Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Royalty Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:RPD vs BNTX, INSM, ROIV: EBITDA Margin % Comparison
For the Biotechnology subindustry, Royalty Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Royalty Pharma EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Royalty Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma (STU:RPD) has a EBITDA Margin % of 89.31% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Royalty Pharma and its competitors. This is 11% above median its historical median of 80.15. Over the past decade, Royalty Pharma's EBITDA Margin % has ranged from 18.94 to 151.79. According to the industry distribution chart, Royalty Pharma ranks #31 out of 944 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Royalty Pharma's EBITDA Margin % too high?
Royalty Pharma's current EBITDA Margin % of 89.31% is 11% above median its 10-year median of 80.15. Over the past 10 years, this metric has ranged from a low of 18.94 to a high of 151.79. Based on the distribution chart, Royalty Pharma ranks #31 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Royalty Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's EBITDA Margin % compare to BNTX and INSM?
According to the Biotechnology industry distribution chart, Royalty Pharma ranks #31 out of 944 companies for EBITDA Margin %. This places Royalty Pharma in the top 3% of its industry — outperforming the majority of peers. Historically, Royalty Pharma's own EBITDA Margin % has ranged from 18.94 to 151.79 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current EBITDA Margin % is 89.31%, which is 11% above median its own 10-year median of 80.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (STU:RPD) is currently considered Significantly Overvalued. The stock's GF Value™ is €32.95, compared to a current price of €48.03 — trading 45.8% above its estimated fair value. The current EBITDA Margin % is 89.31%, which is 11% above median its 10-year median of 80.15. Royalty Pharma's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Royalty Pharma (STU:RPD), the current EBITDA Margin % is 89.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Royalty Pharma (STU:RPD) Overvalued in 2026?
Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued.
The current stock price of €48.03 is trading 45.8% above its estimated GF Value™ of €32.95.
GuruFocus considers Royalty Pharma to be Significantly Overvalued.
Key valuation signals for STU:RPD:
EBITDA Margin %: 89.31% (11% above median its 10-year median of 80.15)
GF Value™: €32.95 vs. price of €48.03 (45.8% above fair value)
No single metric tells the full story. See the STU:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
72GF Score
Get the complete analysis for STU:RPD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:RPD has been successfully added to your 
